Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain.
Anton Paar WP
BIO 2026: Indiana, biopharma investment and the Lilly effect
BIO 2026: Cell and gene therapy firms outline their use of AI in manufacturing
BIO 2026: Drug manufacturers band together to tackle employment challenges
FDA and MHRA forge new regulatory collaboration initiative
Smart pharma is no longer a buzzword: pharma technological breakthroughs at PHARMAP 2026
High-dose biologic delivery to become industry standard
CPHI Europe: Overcoming the unique challenges with high-concentration mAbs
